Funded Grants

Back to results

Interleukin-1 blockade along with hypothermia to prevent cerebral palsy arising from refractory neonatal asphyxia

Project Overview

Neonatal asphyxia and subsequent cerebral palsy (CP) is a severe pathology resulting from lack of oxygen and/or infection-inflammation. This disease still leads to mortality or severe brain injuries and long-term disabilities. Therapeutic hypothermia (decreased body temperature to 33-34°C during 3 days) is the only treatment available for these newborns. Despite hypothermia treatment, more than 50% of these newborns present neurological sequelae. This highlights the need to look for new neuroprotective treatments. This project tests the hypothesis of the efficacy of a targeted anti-inflammatory compound (namely, interleukin-1 receptor antagonist, blocking the action of a key natural inflammatory molecule called interleukin-1 (IL-1)) combined with hypothermia to prevent neonatal cerebral injuries resulting from lack of oxygen and/or infection around birth. The results will provide a better understanding about harmful interactions between the immune and nervous systems. This project will pave the way towards new therapeutic avenues to prevent CP.

Principal Investigator

Mathilde Chevin , McGill University Health Centre

Partners and Donors

McGill University

Project Ongoing

Interleukin-1 blockade along with hypothermia to prevent cerebral palsy arising from refractory neonatal asphyxia

  • Program Type

    Capacity building grants

  • Area of research

    Injury

  • Disease Area

    Other

  • Competition

    Brain Canada - Kids Brain Health Network Training Awards

  • Province

    Québec

  • Start Date

    2018

  • Total Grant Amount

    $70,000

  • Health Canada Contribution

    $35,000